PFS, overall survival, and examples of tumor characteristics pre- and posttreatment. PFS in all evaluable patients (n = 29) (A) and patients stratified according to disease response before ASCT (partial remission [PR], n = 11; CR, n = 18) (B). (C) Representative IHC for pretransplant (pre) samples and posttransplant (post) relapse biopsy samples (original magnification ×200) showing CD3 (white), PD-1 (red), and 4′,6-diamidino-2-phenylindole (DAPI; blue) with corresponding quantification of CD3⁺ infiltrates and PD-1 staining in 4 patients. (D) Representative IHC for pretransplant samples and posttransplant relapse biopsy samples (original magnification ×200) showing Pax5 (pink), CD68 (orange), PD-L1 (green), and DAPI (blue) with corresponding quantification of CD68⁺PD-L1⁺ infiltrates in 4 patients.